Phase 2 N=56 The Effect of Thiamine vs. Placebo on VO2 in Critical Illness
Critically Ill · Respiratory Failure
Primary: Change in VO2 Over Time — 4.2; 4.3 ml/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=58 Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Plerixafor Maximum Tolerated Dose (MTD) [Phase I] — 320 ug/kg
Phase 2 N=126 Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Proportion of Subjects Surviving at 1 Year — 29; 12 Participants
Phase 2 N=164 A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 — -14.08; -19.54 score on a scale — p=0.115
Phase 2 N=22 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
Sickle Cell Disease
Primary: Event -Free Survival Rate — 19 Participants
Phase 2 N=50 Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Maximum Analyte Serum Concentration [Cmax (ng/mL)] — 20.7; 77.6 ng/mL
Phase 2 N=9 A Phase I/II Study of Intratumoral Injection of SD-101
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · Nodal Marginal Zone B-cell Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity (DLT) Events of Ipilimumab Plus a Fixed Dose of SD-101 (1 mg/Week) — 0 Dose-limiting toxicity events
Phase 2 N=60 Prevention of Alcohol Intolerance
Alcohol Sensitivity
Primary: Mean Area of Skin Erythema (Skin Redness) — 3.968; 1.739 centimeters^2
Phase 2 N=44 Curcumin in Treating Patients With Familial Adenomatous Polyposis
Familial Adenomatous Polyposis
Primary: Polyp Number — 22.6; 18.6 polyps — p=0.58
Phase 2 N=5 The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
Lung Injury, Acute
Primary: Heart Rate Assessments Upto Day 7 (Part B) — 87.4; 97.7; 87.9; 95.3 Beats per minute
Phase 2 N=70 To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
Macular Degeneration
Primary: Mean Change From Baseline in Central Retinal/Lesion Thickness (CRLT) as Measured by the Carl Zeiss Meditec Stratus Optical Coherence Tomography (OCT) Scanner at Day 29…
Phase 2 N=40 Vitamin D in Postmenopausal Women at High Risk for Breast Cancer
Breast Cancer
Primary: Change in Serum 25(OH)D — 25; 33 ng/ml
Phase 2 N=17 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Prostate Cancer
Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants
Phase 2 N=50 Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
Schizophrenia
Primary: Change From Baseline in Composite Score of CSSB Following Dosing With GSK239512 — 0.065; 0.016; 0.086; 0.104 Scores on a scale — p=0.7239
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants